Stockreport

Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
PDF -- Expands Ipsen’s Rare Diseases portfolio to include BLU-782, a highly selective investigational ALK2 inhibitor for the treatment of FOP ---- Accelerates global develop [Read more]